Candel Therapeutics Files 2025 Proxy Statement
Ticker: CADL · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1841387
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
Related Tickers: CADL
TL;DR
CADL proxy filed - vote on directors & auditors for June 17 meeting.
AI Summary
Candel Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 29, 2025, for its annual meeting on June 17, 2025. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of the independent auditor.
Why It Matters
This filing provides shareholders with crucial information to make informed voting decisions on company leadership and strategic direction at the upcoming annual meeting.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) and does not contain new material events or financial disclosures beyond what is expected in a proxy statement.
Key Players & Entities
- Candel Therapeutics, Inc. (company) — Registrant
- 0000950170-25-060093 (filing_id) — Accession Number
- 20250429 (date) — Filing Date
- 20250617 (date) — Meeting Date
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is filed by a company to solicit shareholder votes for its annual meeting, providing details on matters to be voted upon, director nominees, executive compensation, and other corporate governance information.
When is Candel Therapeutics' annual meeting scheduled?
Candel Therapeutics' annual meeting is scheduled for June 17, 2025.
What is the filing date of this proxy statement?
This definitive proxy statement was filed on April 29, 2025.
What is the company's primary business according to the filing?
Candel Therapeutics, Inc. is in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) industry, SIC code 2836.
Where is Candel Therapeutics, Inc. headquartered?
Candel Therapeutics, Inc. is headquartered in Needham, MA, with its business address at 117 Kendrick Street, Suite 450.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding Candel Therapeutics, Inc. (CADL).